Bengaluru’s OneSource Pharma Eyes $ 500 M Revenue In The Middle Of License Cliff
Bengaluru-based OneSource Specialized Pharma, a CDMO demerged from Strides Pharma in 2024, is positioned for rapid development, forecasting $ 500 million in earnings by FY 28 with 40 % EBITDA margins. This surge lines up with the approaching expiration of semaglutide licenses and the burgeoning GLP- 1 market.
- Growth Chauffeurs: The firm’s growth is sustained by Drug-Device Combinations, specifically GLP- 1 injection pens.
- Capacity Expansion: Substantial capital investment will certainly raise cartridge capacity to 220 million devices by FY 27, supported by long-term arrangements.
- Regulatory Advantage: OneSource’s USFDA-approved Bengaluru center uses biologics fill-finish and gadget setting up capabilities.